Affiliate Files Intent to Sell $27.1M in Shares from Option Exercise
NAMS has more than doubled off its 52-week low of $14.06.
Summary
An affiliate of NewAmsterdam Pharma Co N.V. has filed a Form 144 to sell 750,000 shares, valued at approximately $27.13 million, stemming from an option exercise and indicating a significant pre-planned liquidity event.
Key Events · Ownership and Investor Activity · NAMS
-
Affiliate Files Intent to Sell Shares
Michael H. Davidson, an affiliate of NewAmsterdam Pharma Co N.V., has filed a Form 144 indicating an intent to sell 750,000 ordinary shares.
-
Significant Proposed Sale Value
The proposed sale has an approximate market value of $27,127,500.00, representing a substantial potential disposition.
-
Shares Acquired via Option Exercise
The shares intended for sale were acquired through an option exercise, with a plan adoption date of September 29, 2025, suggesting a pre-planned liquidity event rather than a discretionary sale based on recent market views.
Analysis · NAMS · Life Sciences
This Form 144 filing indicates a substantial potential sale by Michael H. Davidson, an affiliate, valued at approximately $27.13 million. While the shares originate from an option exercise and the sale appears to be pre-planned (plan adoption date of September 29, 2025), the significant size of this intended disposition could contribute to increased selling pressure on the stock. This filing represents a notably larger potential sale compared to the $8 million in net insider sales observed over the past 90 days, suggesting a significant liquidity event for this insider.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $36.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $14.06 to $42.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.